Minoxidil 2%, 5% and 10% which is better to use?

Minoxidil is one of the most widely used treatments for hair loss. Since its approval by the FDA in the 1980s, its use has spread worldwide and has given rise to a large industry of hair growth products.

Alongside that clinical record, minoxidil has been the subject of intense marketing, and many products promise dramatic results without matching evidence. The question this page answers is a narrow one: what do the trials and the approved labels actually say about 2%, 5% and 10%?

The origin of minoxidil and its path to popularity

Minoxidil was originally developed as an antihypertensive drug, and became notable for an unexpected side effect: hair growth in the patients who took it. That led researchers to test topical application for androgenetic alopecia. In 1988 the FDA approved the first topical 2% minoxidil formulation for male pattern baldness, and in 1991 the approval was extended to women. Higher-strength products followed, and in a randomized trial 5% topical minoxidil produced more hair growth than 2% in men (Olsen et al., 2002).

As minoxidil became established, its presence on the market multiplied. The cosmetic and pharmaceutical industry produced a long list of presentations, formulas and combinations with other ingredients. It is now common to find products combining minoxidil with biotin, caffeine or peptides, marketed as enhancing its effect.

Most of those combinations do not have robust evidence showing better results than minoxidil alone. Regulators have approved minoxidil for hair loss only at specific concentrations, as a single active ingredient; the added ingredients in combination cosmetic products are not part of any approved hair-loss indication.

Minoxidil formulations: are there differences in efficacy?

Minoxidil comes in two main topical formats: solution and foam. Liquid solutions usually contain propylene glycol, which aids absorption but can cause scalp irritation in some people. Foam omits propylene glycol, which reduces irritation and makes application easier.

The approved strengths differ by sex in the United States. The 2% solution is approved for men and women; the 5% solution is approved for men; and the 5% foam is approved for men (twice daily) and for women (once daily). A product being sold does not mean it is approved for a given group, and the 5% solution in particular is not an approved women's product in the US.

What about 10%? There is no approved 10% minoxidil product for hair loss in the US. Compounded and imported 10% and 15% preparations are sold online. In the one head-to-head trial we found (Ghonemy et al. 2021; 90 men, 36 weeks), 10% did not regrow more hair than 5% (5% did better), and irritation and shedding were more marked with 10%. One small trial cannot settle the question, but no trial has shown 10% to be better. Higher concentrations may also increase the amount of drug absorbed into the body. On the current evidence, 5% is the strongest concentration with trial support and regulatory approval; going higher is an experiment with a known downside and an unproven upside.

Reviews of the drug's pharmacology describe several mechanisms: minoxidil is a potassium-channel opener, it dilates blood vessels, and it prolongs the anagen (growth) phase of the hair cycle while shortening telogen (Messenger & Rundegren, 2004).

Only a small fraction — roughly 1.4% according to the product labelling — of topically applied minoxidil is absorbed systemically. Minoxidil is a prodrug: it has to be converted to its active form, minoxidil sulfate, by the scalp enzyme sulfotransferase (SULT1A1). Small studies report that people with higher activity of this enzyme respond better to topical minoxidil. A small 2022 trial (24 men, 60 days, judged by photographs; some authors were from the private company Applied Biology) reported that more men regrew hair when a topical enzyme booster was added (75% vs 33%) (Dhurat et al., 2022); this has not been confirmed in larger trials.

A review of minoxidil in hair disorders also covers oral and sublingual minoxidil, which are not approved for hair loss and are used off-label. That review describes small, mostly uncontrolled reports of oral minoxidil, and its authors concluded that, in their opinion, the benefits of the oral medication did not justify the risk of side effects (Suchonwanit et al., 2019). Since then, a 24-week randomized trial in men (Penha et al. 2024; 90 enrolled, 68 completed) compared oral minoxidil 5 mg once daily with topical 5% twice daily: oral minoxidil was not shown to be better on the main hair-density measure, and 49% of the oral group had unwanted body or facial hair. Most other safety data on low-dose oral minoxidil come from studies without a control group. These are figures from the published literature, not a recommendation. Oral minoxidil is a prescription medicine with cardiovascular effects, and the dose, screening and monitoring are decisions for a prescribing doctor. The US label for minoxidil tablets (approved only for severe high blood pressure) carries a boxed warning: it can cause pericardial effusion (fluid around the heart), occasionally progressing to tamponade, and it can worsen angina (DailyMed, minoxidil tablets).

Finally, what does the community say?

Community users often share their own experience with 5% minoxidil for androgenetic alopecia, and some report combining it with other approaches such as dermarolling and 2% ketoconazole shampoo.

One user reported that after about two and a half months of applying 5% minoxidil twice a day, using a 1.5 mm dermaroller once a week, and washing with 2% ketoconazole shampoo, he saw improvement in the thickness and density of his hair. He described starting to lose hair at 18 and being almost 24 when he posted. Another community member said he was interested in the same approach because he could not tolerate finasteride due to side effects; he was 38 and described diffuse thinning of roughly 40% less density than in his twenties.

These are individual accounts, not trial results, and outcomes vary from person to person. Ketoconazole 2% shampoo is a prescription-strength product in many countries, and dermarolling breaks the skin barrier, which increases how much minoxidil is absorbed.

Talk to a doctor, dermatologist or pharmacist before starting, stopping or combining minoxidil, before using any concentration above 5%, and before using oral or sublingual minoxidil, which is prescription-only and off-label for hair loss. Anyone with a heart or blood-pressure condition, and anyone pregnant or breastfeeding, should get medical advice before using minoxidil in any form.

References

Messenger, A. G., & Rundegren, J. (2004). Minoxidil: mechanisms of action on hair growth. British Journal of Dermatology, 150(2), 186-194. PMID 14996087. https://pubmed.ncbi.nlm.nih.gov/14996087/

Olsen, E. A., Dunlap, F. E., Funicella, T., Koperski, J. A., Swinehart, J. M., et al. (2002). A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. Journal of the American Academy of Dermatology, 47(3), 377-385. PMID 12196747. https://pubmed.ncbi.nlm.nih.gov/12196747/

Suchonwanit, P., Thammarucha, S., & Leerunyakul, K. (2019). Minoxidil and its use in hair disorders: a review. Drug Design, Development and Therapy, 13, 2777-2786. PMID 31496654. https://pubmed.ncbi.nlm.nih.gov/31496654/

Dhurat, R., Daruwalla, S., Pai, S., Kovacevic, M., & McCoy, J. (2022). SULT1A1 (minoxidil sulfotransferase) enzyme booster significantly improves response to topical minoxidil for hair regrowth. Journal of Cosmetic Dermatology, 21(1), 343-346. PMID 34133836. https://pubmed.ncbi.nlm.nih.gov/34133836/

Ghonemy, S., Alarawi, A., & Bessar, H. (2021). Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgenetic alopecia: a trichoscopic evaluation. Journal of Dermatological Treatment, 32(2), 236-241. PMID 31403367. https://pubmed.ncbi.nlm.nih.gov/31403367/

Penha, M. A., Miot, H. A., Kasprzak, M., & Müller Ramos, P. (2024). Oral minoxidil vs topical minoxidil for male androgenetic alopecia: a randomized clinical trial. JAMA Dermatology, 160(6), 600-605. PMID 38598226. https://pubmed.ncbi.nlm.nih.gov/38598226/

Minoxidil Tablets, USP — prescribing information, boxed warning. DailyMed. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0b4fc036-9497-442b-b629-c4b386932789